Dark

Check out our API

CLBS
Caladrius Biosciences, Inc. Common Stock
stock NASDAQ

Inactive

Sep 15, 2022

6.25USD-2.382%(-0.15)2,015,637

Pre-market

0.00USD-100.000%(-6.40)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 5, 2022

05:32AM EST Caladrius Biosciences Shares Up 14% Premarket; Co on Tuesday Announced Participation in Two Upcoming Conferences in January Benzinga

Jan 4, 2022

04:05PM EST Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company),a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced its participation in several industry and investor events. All presentations are pre-recorded and available on-demand through the online conference platforms. GlobeNewswire Inc

Nov 5, 2021

09:30AM EDT Caladrius Biosciences Q3 EPS $(0.12) Beats $(0.15) Estimate Benzinga

Nov 4, 2021

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 28, 2021

08:00AM EDT Caladrius Biosciences to Host Third Quarter 2021 Financial Results GlobeNewswire Inc

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 4, 2021

08:00AM EDT Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company),a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events: GlobeNewswire Inc

Sep 8, 2021

08:00AM EDT Caladrius Biosciences to Present at the H.C. Wainwright 23rd GlobeNewswire Inc

Sep 1, 2021

08:00AM EDT Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Companys Chief Medical Officer (CMO). GlobeNewswire Inc

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 5, 2021

04:41PM EDT Caladrius Biosciences Q2 EPS $(0.10) Beats $(0.14) Estimate Benzinga

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

08:00AM EDT Caladrius Biosciences to Host Second Quarter 2021 Financial GlobeNewswire Inc

Jul 22, 2021

08:00AM EDT Caladrius Biosciences to Present at Zooming with LD GlobeNewswire Inc

Jun 22, 2021

10:51AM EDT Caladrius Bioscience To Start Testing Its CD34+ Cell Therapy in Diabetic Kidney Disease Benzinga

08:04AM EDT Caladrius Biosciences Says To Assess Its CLBS201 CD34+ Cell Therapy In Diabetic Kidney Disease Benzinga

08:00AM EDT Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in GlobeNewswire Inc

Jun 17, 2021

08:00AM EDT Caladrius Biosciences to Present at Noble Capital Markets Virtual GlobeNewswire Inc

Jun 1, 2021

08:30AM EDT Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company),a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events: GlobeNewswire Inc

May 12, 2021

02:15PM EDT Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development Benzinga

08:03AM EDT Caladrius Biosciences Receives $1.4M In Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program Benzinga

08:00AM EDT Caladrius Biosciences Receives $1.4 Million of Non-Dilutive GlobeNewswire Inc

May 6, 2021

04:59PM EDT Caladrius Biosciences Q1 EPS $(0.19) Misses $(0.08) Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 4, 2021

09:00AM EDT Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company),a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events: GlobeNewswire Inc

Apr 29, 2021

08:30AM EDT Caladrius Biosciences to Host First Quarter 2021 Financial Results GlobeNewswire Inc

Mar 8, 2021

08:47AM EST Caladrius Biosciences Reports Orphan Drug Designation For CLBS12 For Treatment Of Buerger's Disease RTTNews

08:46AM EST Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 GlobeNewswire Inc

08:04AM EST Caladrius Biosciences Granted Orphan Drug Designation for CLBS12 for the Treatment of Buerger's Disease Benzinga

Mar 4, 2021

03:08PM EST Caladrius Biosciences Receives FDA Orphan Designation Status For 'GCSF-mobilized autologous CD34+ cells' For Treatment Of Buerger's Disease Benzinga

Mar 3, 2021

12:14PM EST Brookline Capital Maintains Buy on Caladrius Biosciences, Raises Price Target to $10 Benzinga

08:30AM EST Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company),a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021. GlobeNewswire Inc

Feb 25, 2021

04:49PM EST Caladrius Biosciences Q4 EPS $(0.28) Misses $(0.25) Estimate Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 18, 2021

04:05PM EST Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three and twelve months ended December 31, 2020 on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time. GlobeNewswire Inc

10:57AM EST Empery Asset Management Reports In 13G Filing A 5.9% Stake In Caladrius Biosciences Benzinga

08:30AM EST Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo, M.D., Erin Borger, and Cathy Ross to the Companys Board of Directors. GlobeNewswire Inc

Feb 17, 2021

01:59PM EST Caladrius Biosciences, Inc. Closes $65 Million Registered Direct GlobeNewswire Inc

Feb 12, 2021

08:16AM EST Caladrius Biosciences Announces $65M Registered Direct Offerings Of ~24.9M Shares Priced $2.45/Share Benzinga

08:15AM EST Caladrius Biosciences, Inc. Announces $65 Million Registered GlobeNewswire Inc

Jan 29, 2021

04:17PM EST Caladrius Biosciences S-3 Shows Registration For 18.75M Share Common Stock Offering Benzinga

04:16PM EST Caladrius Biosciences Selling Stockholders May Offer And Resell Up To 12.5M Shares Of Company Benzinga

Jan 25, 2021

05:05PM EST Caladrius Biosciences Closes $25.0 Million Private Placement GlobeNewswire Inc

08:30AM EST Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company),a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in the following virtual conferences in February. GlobeNewswire Inc

Jan 21, 2021

09:02AM EST Caladrius Biosciences Reports $25M Private Placement: 12.5M Shares, Warrants At $2/Share Benzinga

09:00AM EST Caladrius Biosciences Announces $25.0 Million Private Placement GlobeNewswire Inc

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

02:49PM EST Mid-Afternoon Market Update: Nasdaq Jumps Over 2%; Gevo Shares Plunge Benzinga

01:39PM EST Mid-Day Market Update: Obalon Therapeutics Jumps On Merger News; Document Security Systems Shares Slide Benzinga

10:17AM EST Shares of clinical-stage biopharmaceutical Caladrius Biosciences, Inc. (CLBS) are surging more than 170% Wednesday morning after the company said it has treated the first patient in its Phase IIb study of CLBS16 as a therapy for coronary microvascular dysfunction. RTTNews

Jan 19, 2021

08:17AM EST Caladrius Biosciences Treats First Patient In Phase 2b FREEDOM Trial Of CLBS16 For Treatment Of Coronary Microvascular Dysfunction Benzinga

08:00AM EST Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom are women GlobeNewswire Inc

Jan 6, 2021

08:30AM EST Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Companys President and CEO, will participate in the following virtual investor conferences during January 2021. GlobeNewswire Inc

Dec 21, 2020

09:50AM EST Life Sciences Investor Forum today announced that the presentations from the December 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. GlobeNewswire Inc

Dec 14, 2020

08:29AM EST Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. GlobeNewswire Inc

08:09AM EST Caladrius Biosciences Offers Year-End Review, Update Of Its Strategic Portfolio Benzinga

08:00AM EST Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company has completed its year-end strategic portfolio product review to optimize the development strategy and priority of each of its programs for 2021 and beyond. GlobeNewswire Inc

Dec 10, 2020

08:30AM EST Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Companys President and CEO, will present a live webcast at the Life Sciences Investor Forum on December 17th. GlobeNewswire Inc

Dec 9, 2020

04:05PM EST Caladrius Biosciences to Present at the 13th Annual LD Micro Main GlobeNewswire Inc

Nov 17, 2020

04:06PM EST Caladrius Biosciences Announces Resignation Of Chief Medical Officer Benzinga

04:05PM EST Caladrius Biosciences Announces the Resignation of Dr. Douglas GlobeNewswire Inc

Nov 10, 2020

08:47AM EST Caladrius Biosciences Highlights Presentation At American Heart Association Meeting Nov. 13 Benzinga

08:30AM EST Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces its presentation at American Heart Associations (AHA) Scientific Sessions, being held virtually November 13-17, 2020. GlobeNewswire Inc

Nov 5, 2020

04:49PM EST Caladrius Biosciences Q3 EPS $(0.29), Inline Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 4, 2020

08:30AM EST Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in three upcoming virtual investor conferences during November 2020. GlobeNewswire Inc

Nov 2, 2020

08:38AM EST Caladrius Biosciences Appoints Anne Whitaker To Board RTTNews

08:30AM EST Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to GlobeNewswire Inc

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

08:30AM EDT Caladrius Biosciences to Host Third Quarter 2020 Financial Results GlobeNewswire Inc

Oct 21, 2020

08:30AM EDT Caladrius Biosciences to Participate in the 8th Annual Chief GlobeNewswire Inc

Oct 8, 2020

08:07AM EDT Caladrius Biosciences Opens Study Of CLBS119 To Repair Coronavirus-Induced Lung Damage Benzinga

08:00AM EDT Caladrius Biosciences Opens Study of CLBS119 to Repair GlobeNewswire Inc

Oct 7, 2020

04:05PM EDT Caladrius Biosciences to Present at the Alliance for Regenerative GlobeNewswire Inc

Oct 6, 2020

04:05PM EDT Caladrius Biosciences to Present at the BIO Investor Forum Digital GlobeNewswire Inc

Sep 21, 2020

08:35AM EDT Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. GlobeNewswire Inc

Sep 14, 2020

08:35AM EDT Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com GlobeNewswire Inc

Sep 10, 2020

08:00AM EDT Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in Landmarks 10th Annual Investing for Cures Virtual Forum being held September 16-17, 2020. GlobeNewswire Inc

Sep 9, 2020

08:05AM EDT Caladrius Biosciences Announces Registration Of HONEDRA Trademark, New Patent In Japan Benzinga

08:00AM EDT Approval received from the Japan Patent Office to use HONEDRA as brand name for CLBS12 in Critical Limb Ischemia and Buergers Disease GlobeNewswire Inc

Sep 8, 2020

12:08PM EDT 2 Conferences Are Going Virtual This Month One On Cannabis And Another Life Sciences Benzinga

08:01AM EDT Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the H.C. Wainwright 22nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020. GlobeNewswire Inc

Sep 3, 2020

08:00AM EDT Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the Advanced Therapies Congress & Expo being held virtually September 8-11, 2020. GlobeNewswire Inc

Aug 21, 2020

08:54AM EDT Clinicaltrials.gov Site Shows Caladrius Biosciences Initiates Trial 'CLBS119 for Repair of COVID-19 Induced Pulmonary Damage' Benzinga

Aug 18, 2020

04:21PM EDT Caladrius Biosciences Files For Shelf Of Up To 969,694 Shares Of Common Stock By Selling Stockholders Benzinga

Aug 14, 2020

08:26AM EDT The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal Benzinga

Aug 13, 2020

04:15PM EDT Caladrius Biosciences Q2 EPS $0.50 Does Not Compare To $(0.39) Estimate Benzinga

04:05PM EDT Clinical programs advanced and expanded with strengthenedcash position GlobeNewswire Inc

08:18AM EDT The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller Benzinga

04:03AM EDT Earnings Scheduled For August 13, 2020 Benzinga

Aug 6, 2020

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Aug 5, 2020

04:58PM EDT Caladrius Biosciences Announces the Resignation of Joseph Talamo As Chief Financial Officer Benzinga

04:05PM EDT Caladrius Biosciences Announces the Resignation of Joseph Talamo, GlobeNewswire Inc

Jul 28, 2020

08:00AM EDT Caladrius Biosciences Appoints Dr. Michael H. GlobeNewswire Inc

Jul 15, 2020

04:49AM EDT 55 Biggest Movers From Yesterday Benzinga

Share